Nemchenko V I
Antibiot Khimioter. 1992 Aug;37(8):9-11.
Clinical trials of cefoperazone (cefobid, Pfizer, USA) were carried out in 49 patients with cardiovascular diseases who had undergone surgical operations. The pathogens of infectious complications were investigated bacteriologically. Good results of the treatment were observed in 43 patients. Allergic reaction developed in 1 patient. Cefoperazone was shown advantageous in treatment of pulmonary complications in the operated patients. It was found possible to use cefoperazone in combination with aminoglycosides. Cefoperazone was found to be one of the drugs of choice in the treatment of aerobic and anaerobic bacteriemia, as well as sepsis after surgical operations on the heart and great vessels. The results on the use of cefoperazone for short-term "perioperative" prophylaxis in cardiosurgery (in accordance with the WHO instructions) are also presented.
对49例接受过外科手术的心血管疾病患者进行了头孢哌酮（头孢必，辉瑞公司，美国）的临床试验。对感染并发症的病原体进行了细菌学调查。43例患者治疗效果良好。1例患者出现过敏反应。头孢哌酮在治疗手术患者的肺部并发症方面显示出优势。发现头孢哌酮可与氨基糖苷类药物联合使用。头孢哌酮被发现是治疗需氧菌和厌氧菌败血症以及心脏和大血管手术后败血症的首选药物之一。还介绍了按照世界卫生组织的指示在心脏手术中使用头孢哌酮进行短期“围手术期”预防的结果。
